MOL PHARMACEUT 润色咨询

MOLECULAR PHARMACEUTICS

出版年份：2004 年文章数：4746 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：8.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2013-01-25 ms1582630781068122

    这个期刊不错，药剂学方面的顶级刊物!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2012-09-03 ms9740844126549404

    不知道怎么样

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2011-10-04 匿名用户

    审稿速度:2.0
    经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2011-10-01 ms3179514010604018

    审稿速度:2.0 | 投稿命中率:95.0
    经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2011-07-12 ms887994580797846

    我的一篇纯计算的，收了，投稿到online三个月。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2011-06-30 ms8415407993286297

    接受率没有那么高。
    大部分稿件通不过内审，没有外审的机会。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2011-06-29 marshlin

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：期刊名：Molecular Pharmaceutics
    出版周期：Bimonthly
    出版ISSN：1543-8384

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2010-09-15 niel

    投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。
    我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=823748, encodeId=e574823e48b8, content=这个期刊不错，药剂学方面的顶级刊物! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ac05413990, createdName=ms1582630781068122, createdTime=Fri Jan 25 17:41:00 CST 2013, time=2013-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=821395, encodeId=be2782139587, content=不知道怎么样 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83d75413971, createdName=ms9740844126549404, createdTime=Mon Sep 03 23:22:00 CST 2012, time=2012-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484718, encodeId=1bfa484e18d4, content=审稿速度:2.0<br>经验分享：审稿人和编辑比较严格，但建设性意见居多，所以还是不错的。在药剂领域的顶尖杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 04 00:03:00 CST 2011, time=2011-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=816350, encodeId=ab7a8163507b, content=审稿速度:2.0 | 投稿命中率:95.0<br>经验分享：审稿意见全面中肯，具有建设性。审稿人建议添加实验数据，但做了详细的解释和申述后，只添加了必要的数据。接受后文字编辑效率高，校样稿和见刊速度超快。顺便一提，彩图也免费！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01255414130, createdName=ms3179514010604018, createdTime=Sat Oct 01 17:07:00 CST 2011, time=2011-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815284, encodeId=34c08152844d, content=我的一篇纯计算的，收了，投稿到online三个月。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d445414141, createdName=ms887994580797846, createdTime=Tue Jul 12 15:02:00 CST 2011, time=2011-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815072, encodeId=c51b8150e236, content=接受率没有那么高。<br> 大部分稿件通不过内审，没有外审的机会。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40eb5414087, createdName=ms8415407993286297, createdTime=Thu Jun 30 10:20:00 CST 2011, time=2011-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=475567, encodeId=1c8a4e5567be, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：期刊名：Molecular Pharmaceutics <br> 出版周期：Bimonthly <br> 出版ISSN：1543-8384, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e7c34764, createdName=marshlin, createdTime=Wed Jun 29 12:10:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=471843, encodeId=89504e184394, content=投稿有难度，但是比想象的简单，关键是大胆尝试，当然也要掂量自己文章的分量。 <br> 我最初投稿的时候是一时冲动，投完以后立马希望来个速决，以便转投其它杂志。但是编辑却迟迟没有给rejection，一个月后居然让我修改。三位审稿人，一位提出了很多问题（的确也比较尖锐），最后意见是在大修和拒稿之间犹豫；另外两位则比较客气，小修接收。编辑权衡了一下，给了个大修。修改很费力，前后一个半月。期间编辑来信提醒：再有一个月就到期了（修改期限2个月），让人倍感温暖。岂不知我将修改后文章投稿后，迟迟不见回复（一般ACS杂志效率非常高，二审2周左右），让我又担心这篇文章的命运来。昨日，终于来消息，还是小修一下，审稿人怕我瞎改，将这句话改怎么说，怎么改的句子都给在comments中了，也算是用心良苦。 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=600, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=niel, createdTime=Wed Sep 15 15:38:00 CST 2010, time=2010-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=470277, encodeId=2da84e0277f6, content=没有说的那么可怕 大胆去试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Feb 23 16:29:00 CST 2010, time=2010-02-23, status=1, ipAttribution=)]
    2010-02-23 匿名用户

    没有说的那么可怕 大胆去试试

    0

共56条页码: 3/6页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分